Literature DB >> 4049465

Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.

R G Dickinson, W D Hooper, M Patterson, M J Eadie, B Maguire.   

Abstract

Urinary excretion of p-hydroxyphenytoin and its glucuronide conjugate was measured in eight healthy young adults in a comparative bioavailability study of oral sodium phenytoin (approximately 5 mg/kg/dose). Among these subjects the percentage of the phenytoin dose converted to p-hydroxyphenytoin and appearing in urine was relatively similar (mean 79%, range 67-88%). The great majority of the p-hydroxyphenytoin appeared in urine as conjugates; only 1.4-3.4% of the excreted p-hydroxyphenytoin was in the form of unconjugated metabolite. The proportion of a single phenytoin dose excreted in urine as p-hydroxyphenytoin or its conjugate increased from the first dose (mean +/- SD) 74.9 +/- 4.6% to the second dose, given 2 weeks later 79.3 +/- 4.6% (p less than 0.05). This finding suggests that autoinduction of phenytoin metabolism may occur after relatively brief exposure to the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4049465     DOI: 10.1097/00007691-198507030-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

3.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

4.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 5.  Influence of efflux transporters on drug metabolism: theoretical approach for bioavailability and clearance prediction.

Authors:  Pietro Fagiolino; Marta Vázquez; Rosa Eiraldi; Cecilia Maldonado; Alejandro Scaramelli
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Phenytoin metabolism during pregnancy.

Authors:  M J Eadie; G E McKinnon; R G Dickinson; W D Hooper; C M Lander
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Assessment of inter-individual variability in predicted phenytoin clearance.

Authors:  Thomas M Polasek; Sebastian Polak; Matthew P Doogue; Amin Rostami-Hodjegan; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

9.  CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Authors:  Amarjit S Chaudhry; Thomas J Urban; Jatinder K Lamba; Angela K Birnbaum; Rory P Remmel; Murali Subramanian; Stephen Strom; Joyce H You; Dalia Kasperaviciute; Claudia B Catarino; Rodney A Radtke; Sanjay M Sisodiya; David B Goldstein; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

10.  Co-regulation of phenytoin and tolbutamide metabolism in humans.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; C J Doecke; M E McManus; L N Sansom; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.